Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.720
-0.020 (-1.15%)
Dec 20, 2024, 4:00 PM EST - Market closed
Fortress Biotech Revenue
Fortress Biotech had revenue of $14.63M in the quarter ending September 30, 2024, a decrease of -7.13%. This brings the company's revenue in the last twelve months to $81.50M, up 31.51% year-over-year. In the year 2023, Fortress Biotech had annual revenue of $84.51M with 11.58% growth.
Revenue (ttm)
$81.50M
Revenue Growth
+31.51%
P/S Ratio
0.36
Revenue / Employee
$438,177
Employees
186
Market Cap
47.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
iCAD, Inc. | 18.94M |
Omega Therapeutics | 8.10M |
Nutriband | 2.02M |
vTv Therapeutics | 1.00M |
Exicure | 500.00K |
Inovio Pharmaceuticals | 203.41K |
FBIO News
- 8 days ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 5 weeks ago - Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 5 weeks ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewsWire
- 2 months ago - Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - GlobeNewsWire
- 2 months ago - Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 3 months ago - Fortress Biotech to Participate in October 2024 Investor Conferences - GlobeNewsWire